Future regulation of laboratory-developed tests (LDTs) may not be as clear as it once appeared. On Sept. 30, Congress passed a short-term resolution to keep the federal government funded. As part of the move, a proposed bill to increase oversight of LDTs has been sidelined, at least for now, according to law firm Ropes & […]
October 10, 2022 Intelligence: Late-Breaking Lab News
- By Robert Michel
- > From the Volume XXIX, No. 14 - October 10, 2022 Issue
- Tags: Abbot, Abbott Laboratories, Agendia, AstraZeneca, Babson Diagnostics, Beckman Coulter Diagnostics, Cerner, Clinical Laboratory Improvement Amendments Act of 1988, CompuGroup Medical US, data exchange, David Vinson, digital pathology, Dominic Weilbaecher, Fierce Healthcare, Google Cloud, Google Imaging, IVCT Development Act of 2022, Karan Arora, laboratory-developed test, labotix, ldt, Med Fusion, Mindera, Novartis, Ortho Clinical Diagnostics, Peter Manes, Pfizer, Quest Diagnostics, Ropes and Gray, specialty laboratories, VALID Act, Vanderbilt University Medical Center
